Document Detail


Exposure to bleomycin, etoposide, and cis-platinum alters rat sperm chromatin integrity and sperm head protein profile.
MedLine Citation:
PMID:  22402960     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Testicular cancer, currently the most common cancer affecting men of reproductive age, is one of the most curable malignancies due to the progress made in the early diagnosis and effective treatment of this disease. The coadministration of bleomycin, etoposide, and cis-platinum (BEP) has brought the 5-yr survival rate of testis cancer patients to over 90%. However, this treatment results in reproductive chemotoxic effects. We assessed the effect of BEP treatment on sperm chromatin integrity and sperm head protein profiles of adult male Brown Norway rats following 9 wk of treatment with BEP and in animals treated for 9 wk and then subjected to a 9-wk recovery period. Both the susceptibility of DNA to denaturation and the number of strand breaks were significantly increased in mature sperm following 9 wk of treatment with BEP; proteomic analysis revealed that the expression of several proteins, including HSP90AA1 and HSP90B1, was markedly affected. Following a 9-wk recovery period, mature sperm did not show significant DNA damage, indicating that repair had potentially occurred. Interestingly, the protamination level of the sperm of these animals was significantly decreased, while histones HIST1H1D (H1.2), HIST1H4B (H4), HIST2H2AA3 (H2A1), and HIST1H2BA (H2B1A) were concomitantly up-regulated; this was not observed in the sperm immediately following 9 wk of treatment. Thus, there are persistent effects on proteins in sperm heads from the cauda epididymidis 9 wk posttreatment, in the absence of DNA strand breaks. We suggest that these effects on the sperm head proteome may contribute to long-lasting adverse effects in the progeny of BEP-exposed males.
Authors:
Jennifer Maselli; Barbara F Hales; Peter Chan; Bernard Robaire
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-05-31
Journal Detail:
Title:  Biology of reproduction     Volume:  86     ISSN:  1529-7268     ISO Abbreviation:  Biol. Reprod.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-06-01     Completed Date:  2012-09-17     Revised Date:  2012-12-06    
Medline Journal Info:
Nlm Unique ID:  0207224     Medline TA:  Biol Reprod     Country:  United States    
Other Details:
Languages:  eng     Pagination:  166, 1-10     Citation Subset:  IM    
Affiliation:
Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / adverse effects*,  therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects*,  therapeutic use
Bleomycin / adverse effects*,  therapeutic use
Chromatin / drug effects*,  metabolism
Cisplatin / adverse effects*,  therapeutic use
DNA Breaks / drug effects
Etoposide / adverse effects*,  therapeutic use
Histones / metabolism
Male
Protamines / metabolism
Proteomics
Rats
Sperm Head / drug effects*
Spermatogenesis / drug effects
Spermatozoa / drug effects
Testicular Neoplasms / drug therapy
Up-Regulation
Grant Support
ID/Acronym/Agency:
MOP-86636//Canadian Institutes of Health Research
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Chromatin; 0/Histones; 0/Protamines; 11056-06-7/Bleomycin; 15663-27-1/Cisplatin; 33419-42-0/Etoposide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Psychometric properties of the Farsi version of effort-reward imbalance questionnaire: a longitudina...
Next Document:  Characterization of cumulus expansion-inhibiting factor (CEIF) in goat follicles.